HuGE Literature Finder
Records
1
-
13
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast cancer research and treatment 2020 May . O'Donnell Peter H, Trubetskoy Vassily, Nurhussein-Patterson Ashley, Hall Julianne P, Nath Aritro, Huo Dezheng, Fleming Gini F, Ingle James N, Abramson Vandana G, Morrow P K, Storniolo Anna Maria, Forero Andres, Van Poznak Catherine, Liu Minetta C, Chang Jenny C, Merkel Douglas E, Peppercorn Jeffrey M, Rugo Hope S, Dees E Claire, Hahn Olwen M, Hoffman Philip C, Rosner Gary L, Huang R Stephanie, Ratain Mark J, Cox Nancy, Olopade Olufunmilayo I, Wolff Antonio C, Dolan M Eileen, Nanda Rita, |
| Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines. Journal of gastrointestinal oncology 2018 Jun 9 (3): 416-424. Khushman Moh'd, Patel Girijesh Kumar, Hosein Peter Joel, Laurini Javier Ariel, Cameron Daniel, Clarkson David Roland, Butler Thomas Wayne, Norden Carole Wiseman, Baliem Wilma, Jones Vanessa, Bhadkamkar Sanjyot, Nelson Cindy, Lee Frances, Singh Ajay P, Taylor William |
| DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer chemotherapy and pharmacology 2017 Nov . Nahid Noor Ahmed, Apu Mohd Nazmul Hasan, Islam Md Reazul, Shabnaz Samia, Chowdhury Surid Mohammad, Ahmed Maizbha Uddin, Nahar Zabun, Islam Md Siddiqul, Islam Mohammad Safiqul, Hasnat Ab |
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
| Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies. Clinical biochemistry 2016 Jul . Galarza Andrés Fernando Andrade, Linden Rafael, Antunes Marina Venzon, Hahn Roberta Zilles, Raymundo Suziane, da Silva Anne Caroline Cezimbra, Staggemeier Rodrigo, Spilki Fernando Rosado, Schwartsmann Gilber |
| Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
| Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. International journal of clinical and experimental medicine 2014 7 (12): 5857-61. Sun Wenhui, Yan Chungen, Jia Shaochang, Hu Jianh |
| DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 2013 Aug 14 (11): 1255-72. Terrazzino Salvatore, Cargnin Sarah, Del Re Marzia, Danesi Romano, Canonico Pier Luigi, Genazzani Armando |
| Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 May 17 (10): 3455-68. Deenen Maarten J, Tol Jolien, Burylo Artur M, Doodeman Valerie D, de Boer Anthonius, Vincent Andrew, Guchelaar Henk-Jan, Smits Paul H M, Beijnen Jos H, Punt Cornelis J A, Schellens Jan H M, Cats Annemie |
| Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 May 26 (13): 2131-8. Schwab Matthias, Zanger Ulrich M, Marx Claudia, Schaeffeler Elke, Klein Kathrin, Dippon Jürgen, Kerb Reinhold, Blievernicht Julia, Fischer Joachim, Hofmann Ute, Bokemeyer Carsten, Eichelbaum Michel, |
| [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
| The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population. Avicenna journal of medical biotechnology 0 12 (3): 157-164. Abbasian Mohammad Hadi, Ansarinejad Nafiseh, Abbasi Bahareh, Iravani Masoud, Ramim Tayeb, Hamedi Fahime, Ardekani Ali |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jan 20, 2022
- Content source: